Answers are grounded in this paper and cite their sources.
Background Breast cancer is the most frequently diagnosed cancer in women worldwide, and its therapeutic landscape has been repeatedly reshaped by new drug classes. However, the scale and evolution of its clinical drug-development activity have not been comprehensively mapped. We aimed to characterise global trends in drug clinical trials for breast cancer in women, including therapeutic focus, target populations, trial design, and reporting practices. Methods In this study, we identified interventional trials of drug or biological therapies for breast cancer in women registered in ClinicalTrials.gov , the European Union Clinical Trials Register, the Clinical Trials Information System, and ISRCTN. Records were deduplicated across registries at the trial level. We characterised trial volume, geography, sponsorship, therapeutic focus, target population, design, and results reporting. Temporal trends over 2000–2025 were assessed using segmented log-linear regression. Results We identified 8,224 trials, with an aggregate registry-reported enrollment of 1,853,069 participants.Annual trial initiations increased from 87 in 2000 to 472 in 2025 (annual percent change +18.8% in 2000–2006, −4.6% in 2007–2010, and +4.7% in 2011–2025). Among the 7,164 trials with available site-country information, 52.5% included at least one site in the United States and 19.8% included at least one site in China. Academic or hospital sponsors led approximately 60% of all trials, whereas industry sponsors led about one-third. Therapeutic focus shifted from cytotoxic chemotherapy towards endocrine, HER2-directed, CDK4/6-inhibitor, immune-checkpoint, and antibody–drug-conjugate therapies. Immune-checkpoint trials increased from 34 in 2011–2015 to 288 in 2016–2020 before declining to 262 in 2021–2025. Among the 7,809 trials with preferred records from ClinicalTrials.gov , 58.4% were single-arm and 40.1% were randomised. Results had been posted for 28.1% of all trials, and 12.6% ended early. Conclusion Breast cancer drug-trial activity has expanded substantially and shifted towards targeted and immune-based therapies, with increasing concentration on advanced disease. Greater use of comparative designs and more complete results reporting could strengthen the evidence generated by this expanding clinical development landscape.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: